iMBioRay

Imbioray (Hangzhou) Biopharmaceutical Co., Ltd. mainly engages in the development of CAR-NK cell therapy drugs, focusing on solid tumors, hematological tumors, and virus-related diseases. The company received key support as a Class A project under the Binjiang District’s 5050 Program at its establishment. Imbioray owns globally leading tiNK™ and CAR-baNK™ cell technology platforms. Based on its proprietary platform technologies, the company has developed multiple universal off-the-shelf allogeneic NK and CAR-NK cell therapy products. Clinical trials have preliminarily demonstrated their safety and efficacy, and several new drugs for solid tumors and hematological tumors are currently advancing into clinical stages.